Parallel to Biologics, another trend is the rapidly growing interest in Biosimilars. This is clearly fueled by the expiry of patents due on at least 48 biologics with a combined global market size of nearly $ 73 billion across the globe over the next decade. There is an increasing demand for low-cost medicines from healthcare players around the world as they struggle to contain soaring healthcare

• Spending on Biosimilars globally was $ 693 million in 2011.
• Estimated increase to $ 4-6 billion or 2% of Biologic spending by 2016.
• Around 410 odd Biosimilars in development or close to securing regulatory approval and mainly in the class of Monoclonal Antibodies, Insulin and CSF drugs.